<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161016</url>
  </required_header>
  <id_info>
    <org_study_id>map3-2014</org_study_id>
    <nct_id>NCT02161016</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft</brief_title>
  <official_title>A Radiographic and Clinical Outcomes Study Evaluating map3® Cellular Allogeneic Bone Graft in Patients Undergoing Bone Grafting in the Foot/Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RTI Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot study in patients requiring surgical fusion in the foot or ankle.
      Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem
      cells. This cohort study will enroll 24 patients total at 1 site. After subjects have signed
      an informed consent, the baseline visit and examinations will be completed. Patients will be
      evaluated at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      map3® Cellular Allogeneic Bone Graft provides the desired osteoconductive, osteoinductive and
      osteogenic potential capacities which are essential to optimal fracture healing when bone
      grafts are implanted. It offers viable MAPC-class cells on a scaffold comprised of
      demineralize bone matrix (DBM) and cortical cancellous chips. map3® Cellular Allogeneic Bone
      Graft is considered an allograft, and as such, is indicated for bone repair for orthopaedic
      indications where autograft is employed. The primary goal of this study is to evaluate the
      outcomes in bone grafts of the foot or ankle using a stem cell modified allograft (map3®
      Cellular Allogeneic Bone Graft). The study endpoints will be objectively determined via
      x-rays and CT scan to assess bony fusion, extremity evaluation using the AFAS and subjective
      patient scores for foot disabilities and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOFAS Foot-and-Ankle Score</measure>
    <time_frame>24 months</time_frame>
    <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36 Score</measure>
    <time_frame>24 months</time_frame>
    <description>The SF-36 is a survey for health and well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foot Ankle Disability Index</measure>
    <time_frame>24 months</time_frame>
    <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT Scan</measure>
    <time_frame>6 months</time_frame>
    <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Full Weight-bearing</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Foot Deformities, Acquired</condition>
  <condition>Disorder of Joint of Foot</condition>
  <condition>Fracture of Foot</condition>
  <condition>Deformity of Bone</condition>
  <arm_group>
    <arm_group_label>map3 allogeneic bone graft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>map3</intervention_name>
    <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
    <arm_group_label>map3 allogeneic bone graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study subjects will be limited to patients with foot/ankle pathologies requiring
             fusion, which include midfoot, hindfoot, ankle, double and triple arthrodesis using
             open surgical technique with supplemental bone graft substitute.

          -  Life expectancy of at least twenty four (24) months

          -  Ability to give written informed consent

          -  All subjects will have a minimum age of eighteen (18) years and a maximum of eighty
             (80) years.

          -  Both male and non-pregnant female subjects will be included.

          -  To facilitate follow-up, study subjects will be limited to the local geographic area
             of the study site and must be willing to use the rehabilitation facility and physical
             therapy schedule assigned by the surgeon.

          -  All subjects must be able to read, write, and comprehend instructions and guidelines
             in English and understand (and sign as an acknowledgment of their understanding) an
             informed consent declaration

        Exclusion Criteria:

          -  Patients who have been diagnosed with Charcot foot

          -  Patients requiring osteotomies or undergoing a revision surgery for non-union

          -  Patients with additional lower limb injuries requiring concomitant procedures not
             related to the current foot/ankle procedure

          -  Patients with soft tissue compromise involving open and/or infected wounds on the
             study limb

          -  Patients requiring any other bone grafting product other than study product (map3®
             Cellular Allogeneic Bone Graft) e.g. rhBMP2 (recombinant human bone morphogenetic
             protein 2).

          -  Patients with confirmed diagnosis of abnormal lower limb vasculature or peripheral
             vascular disease

          -  Patients with a high Body Mass Index ( BMI &gt; 35)

          -  Diagnosis of osteonecrosis, metabolic bone diseases or gout

          -  Diabetic patients who are insulin dependent

          -  Patients who have received any treatment within the past 12 months which may interfere
             with bone metabolism (bisphosphonates and/or calcitonin).

          -  Patients using glucocorticoids &gt; 10 mg/day

          -  Chronic use (≥ 90 days) of non-steroidal anti-inflammatory drugs (NSAIDS)

          -  Patients with active cancer or a history of any cancer

          -  Known allergies to Dimethyl Sulfoxide (DMSO) and/or Human Serum Albumin (HSA)

          -  Pregnant or lactating females or who are capable of reproduction and will not take
             acceptable measures to prevent reproduction during the study

          -  Patients who have tested positive for HTLV, HIV, hepatitis B or hepatitis C, have
             rheumatoid arthritis, an autoimmune disease or are on chronic immunosuppressive
             medications

          -  Require chronic use (≥ 90 days) of anticoagulation therapy

          -  Active smokers unwilling to comply with surgeons instructions to stop smoking seven
             (7) days prior to surgery through three (3) month post-op visit

          -  History of alcohol or drug abuse within 90 days of screening

          -  Patients currently enrolled or have been enrolled in clinical studies evaluating
             investigational devices, pharmaceuticals or biologics within 90 days of enrollment.

          -  Patients unable to give written informed consent and any vulnerable patient population

          -  Inability to comply with all requirements of this investigation, as well as follow the
             instructions of the physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Radnay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Guyton GP, Miller SD. Stem cells in bone grafting: Trinity allograft with stem cells and collagen/beta-tricalcium phosphate with concentrated bone marrow aspirate. Foot Ankle Clin. 2010 Dec;15(4):611-9. doi: 10.1016/j.fcl.2010.09.003. Review.</citation>
    <PMID>21056860</PMID>
  </reference>
  <reference>
    <citation>Clements JR. Use of allograft cellular bone matrix in multistage talectomy with tibiocalcaneal arthrodesis: a case report. J Foot Ankle Surg. 2012 Jan-Feb;51(1):83-6. doi: 10.1053/j.jfas.2011.09.002. Epub 2011 Oct 20.</citation>
    <PMID>22014833</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Foot Deformities</mesh_term>
    <mesh_term>Foot Deformities, Congenital</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Foot Deformities, Acquired</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>withdrawn by IRB</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AOFAS Foot-and-Ankle Score</title>
        <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>AOFAS Foot-and-Ankle Score</title>
          <description>The American Orthopaedic Foot and Ankle Society score returns an indexed score, from 0 - 100, to assess clinical outcomes following foot /ankle surgery.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Score</title>
        <description>The SF-36 is a survey for health and well-being.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Score</title>
          <description>The SF-36 is a survey for health and well-being.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Foot Ankle Disability Index</title>
        <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Foot Ankle Disability Index</title>
          <description>The Foot Ankle Disability Index (FADI) is a self-report of function that assesses activities of daily living, with scores ranging from 0 to 100.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CT Scan</title>
        <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>CT Scan</title>
          <description>A CT scan will be done at 6 months in order to assess bone fusion.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Full Weight-bearing</title>
        <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>map3 Allogeneic Bone Graft</title>
            <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Full Weight-bearing</title>
          <description>This will be the time from the date of surgery until the patient has full, unassisted weight bearing, and will be measured in weeks.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>map3 Allogeneic Bone Graft</title>
          <description>Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
map3: Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Waite</name_or_title>
      <organization>RTI Surgical</organization>
      <phone>386-418-8888</phone>
      <email>rwaite@rtix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

